Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
Biotechnology Progress|January 11, 2016
Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysisArmin Mooranian, Rebecca Negrulj, Hani Al-Salami, et al.
Frontiers in Pharmacology|April 22, 2022
Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel DiseaseSlavica Lazarević, Maja Đanic, Hani Al-Salami, et al.
Pharmaceutical Research|September 4, 2021
Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid InvolvementJustin Pickering, Rachel Wong, Hani Al-Salami, et al.
Analytical and Bioanalytical Chemistry|September 13, 2018
Quantification of BSA-loaded chitosan/oligonucleotide nanoparticles using reverse-phase high-performance liquid chromatographyChun Y Wong, Jorge Martinez, Hani Al-Salami, et al.
Pharmaceutical Development and Technology|April 21, 2017
The effect of molecular weights of microencapsulating polymers on viability of mouse-cloned pancreatic β-cells: biomaterials, osmotic forces and potential applications in diabetes treatmentArmin Mooranian, Ryu Takechi, Emma Jamieson, et al.
Pharmaceutical Research|March 15, 2017
Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines AnalysisArmin Mooranian, Ryu Tackechi, Emma Jamieson, et al.
Current Drug Delivery|February 19, 2014
Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in miceMarc Fakhoury, Michael Coussa-Charley, Hani Al-Salami, et al.
Therapeutic Delivery|February 7, 2023
β-cyclodextrin based nano gene delivery using pharmaceutical applications to treat Wolfram syndromePiumi Christina Quintas, Hani Al-Salami, Abigail Pfaff, et al.
Pharmacological Research|June 30, 2019
Semisynthetic bile acids: a new therapeutic option for metabolic syndromeSlavica Lazarević, Maja Đanić, Svetlana Goločorbin-Kon, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 30, 2011
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic ratsHani Al-Salami, Grant Butt, Ian Tucker, et al.
Pageof 19